Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | PNP | P00491 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 2/20 | 0.40 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9393705 | 1.00 | LMNA (0.49) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL6559406 | 1.00 | LMNA (0.49) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL7200818 | 1.00 | LMNA (0.49) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL7915780 | 0.92 | UPP1 (0.44) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL7915783 | 0.92 | UPP1 (0.44) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL7516274 | 0.92 | PNP (0.52) | LMNATP53UPP1P2RY1PNP | |
| SCHEMBL10624665 | 0.92 | UPP1 (0.43) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL10624661 | 0.92 | UPP1 (0.43) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL13664950 | 0.91 | LMNA (0.49) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL15031043 | 0.91 | LMNA (0.49) | LMNATP53ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0173059-B1 | METHOD FOR THE PRODUCTION OF 2'-DEOXYADENOSINE COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 1989-11-29 | — | — | EP | claimed |
| US-4760137-A | Method for the production of 2'-deoxyadenosine compounds | BRIGHAM YOUNG UNIVERSITY (US) | 1988-07-26 | — | — | US | claimed |
| EP-0173059-A2 | Method for the production of 2'-deoxyadenosine compounds | BRIGHAM YOUNG UNIVERSITY (US) | 1986-03-05 | — | — | EP | claimed |
| EP-0731807-B1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS INC (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-0801571-B1 | SOLUBLE 2-CHLORO-2'-DEOXYADENOSINE FORMULATIONS | ORTHO PHARMA CORP (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-0799046-B1 | STABLE SOLUTIONS OF 2-CHLORO-2'-DEOXYADENOSINE | ORTHO PHARMA CORP (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6232463-B1 | CROSSLINKING OLIGONUCLEOTIDES CONTAINING PURINE ANALOGS HAVING REACTIVE SITES ON THE NUCLEOBASE AND ON A SUGAR MOIETY; ANTISENSE AGENTS | ISIS PHARMACEUTICALS, INC. | 2001-05-15 | — | — | US | disclosed |
| US-6166199-A | N-2 substituted purines | ISIS PHARMACEUTICALS, INC (US) | 2000-12-26 | — | — | US | disclosed |
| US-5811534-A | PURINE-BASED COMPOUNDS FOR INCLUSION INTO OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-22 | — | — | US | disclosed |
| US-5808027-A | ANTISENSE AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5681822-A | Shelf stable solutions of cladribine in benzyl alcohol | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-10-28 | — | — | US | disclosed |
| US-5641757-A | Shelf stable formulations of cladribine in water are disclosed which contain benzyl alcohol, m-cresol, a buffer and sodium chloride or a solubilizing agent such as propylene glycol or polyethylene glycol | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0547910-B1 | A process for preparing 2-chloro-2'-deoxyadenosine | ORTHO PHARMA CORP (US) | 1997-03-05 | — | — | EP | disclosed |
| US-5587469-A | USEFUL AS ?ANTISENSE AGENTS? THAT ARE CAPABLE OF SPECIFIC HYBRIDIZATION WITH A NUCLEOTIDE SEQUENCE OF AN RNA | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-24 | — | — | US | disclosed |
| US-5459255-A | For incorporation into oligonucleotides, cleaving RNA site specifically | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| EP-0547910-A1 | A process for preparing 2-chloro-2'-deoxyadenosine | ORTHO PHARMACEUTICAL CORPORATION (US) | 1993-06-23 | — | — | EP | disclosed |
| US-5208327-A | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine | ORTHO PHARMACEUTICAL CORPORATION (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0173059-B1 | METHOD FOR THE PRODUCTION OF 2'-DEOXYADENOSINE COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 1989-11-29 | — | — | EP | disclosed |
| US-4760137-A | Method for the production of 2'-deoxyadenosine compounds | BRIGHAM YOUNG UNIVERSITY (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0173059-A2 | Method for the production of 2'-deoxyadenosine compounds | BRIGHAM YOUNG UNIVERSITY (US) | 1986-03-05 | — | — | EP | disclosed |